| 姜洁,刘浩楠,韩正祥.吉西他滨 /白蛋白紫杉醇联合安罗替尼及 PD-1抑制剂一线治疗晚期胰腺癌的疗效及安全性[J].安徽医药,2026,30(2):376-381. |
| 吉西他滨 /白蛋白紫杉醇联合安罗替尼及 PD-1抑制剂一线治疗晚期胰腺癌的疗效及安全性 |
| Efficacy and safety of gemcitabine/nab-paclitaxel combined with anlotinib and PD-1 inhibitor as first-line treatment for advanced pancreatic cancer |
| |
| DOI：10.3969/j.issn.1009-6469.2026.02.031 |
| 中文关键词: 胰腺肿瘤 化疗 安罗替尼 细胞程序性死亡受体 -1抑制剂 吉西他滨 |
| 英文关键词: Pancreatic neoplasms Chemotherapy Anlotinib |
| 基金项目:江苏省高层次卫生人才“六个一工程” A类项目( LGY2020006) |
|
| 摘要点击次数: 645 |
| 全文下载次数: 198 |
| 中文摘要: |
| 目的初步探讨吉西他滨 /白蛋白紫杉醇( AG方案)联合安罗替尼及细胞程序性死亡受体 -1(PD-1)抑制剂一线治疗晚期胰腺癌的临床疗效及不良反应。方法回顾性分析徐州医科大学附属医院 2019年 8月至 2023年 3月收治的晚期胰腺癌病人 50例。根据治疗方案分为两组，其中化疗组( AG方案) 26例，联合治疗组( AG方案联合安罗替尼及 PD-1抑制剂) 24例。比较两组无进展生存时间( PFS)、总生存时间( OS)、客观缓解率( ORR)、疾病控制率( DCR)和不良反应。使用 Kaplan-Meier方法绘制生存曲线，并采用 log-rank检验比较两组生存差异。使用 Cox回归模型进行单因素和多因素分析确定影响 OS的独立危险因素。结果联合治疗组的中位 PFS明显长于化疗组( 5.6个月比 4.4个月， P=0.012)且中位 OS也明显长于化疗组( 12.8个月比 7.8个月， P=0.007)。两组病人的 ORR差异无统计学意义( 33.3%比 23.1%，P=0.420)，，联合治疗组的 DCR(83.3%比 57.7%， P=0.048)显著优于化疗组。两组病人以 1~2级不良反应为主，无不良反应相关死亡事件发生。结论与单纯化疗相比， AG方案联合安罗替尼及 PD-1抑制剂一线治疗晚期胰腺癌的疗效更好，且不良反应可控。 |
| 英文摘要: |
| Objective To investigate the clinical efficacy and adverse reactions of gemcitabine/nab-paclitaxel (AG regimen) com-bined with anlotinib and PD-1 inhibitor as first-line treatment for advanced pancreatic cancer (PC).Methods Fifty patients with ad-vanced PC treated in the Affiliated Hospital of Xuzhou Medical University from August 2019 to March 2023 were retrospectively ana-lyzed. According to the treatment regimen, the patients were divided into two groups, including 26 patients in the chemotherapy group(AG regimen) and 24 patients in the combined treatment group (AG regimen combined with anlotinib and PD-1 inhibitor). Overall sur-vival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and adverse reactions were com-pared between the two groups. The survival curves of the two groups were drawn using the Kaplan-Meier method, and the differences in PFS and OS between the two groups were compared by Log-rank test. Univariate and multivariate analyses were performed using Coxproportional hazard regression models to identify independent risk factors influencing prognosis.Results The median OS and PFS in the combined treatment group were significantly longer than those in the chemotherapy group (OS, 12.8 vs. 7.8 months, P=0.007; PFS, 5.6 vs. 4.4 months, P=0.012). There was no significant difference in ORR between the two groups (33.3% vs. 23.1%, P=0.420), and the DCR in the combined treatment group (83.3% vs. 57.7%, P=0.048) was significantly better than that in the chemotherapy group. Grade 1-2 adverse reactions were predominant in both groups, and no adverse reaction related deaths occurred.Conclusion Compared with chemotherapy alone, AG regimen combined with anlotinib and PD-1 inhibitor has better efficacy in the first-line treatment of advanced PC, and the adverse reactions are controllable. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
